Glaucoma Pipeline Therapeutics Assessment Report 2024 (Updated)

DelveInsight's, "Glaucoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Glaucoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Glaucoma Research. Learn more about our innovative pipeline today! @ Glaucoma Pipeline Outlook- https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Glaucoma Pipeline Report
• In November 2024:- AbbVie- XEN45 is an approved device for the treatment of glaucoma implanted using the ab interno approach (inside the eye). XEN45 implanted using the ab externo approach (outside the eye) is being studied in this study. Approximately 65 participants aged 45 years or older with open-angle glaucoma will be enrolled in this study at approximately 22 sites in the United States.
• In November 2024;- Perfuse Therapeutics Inc.- This clinical study has two phases: Phase 1 and Phase 2a. Phase 1 is an open-label, SAD study to investigate the ocular and systemic safety and tolerability of two dose levels of PER-001, in participants with advanced OAG. Phase 1 will enroll up to approximately 12 participants.
• DelveInsight's Glaucoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Glaucoma treatment.
• The leading Glaucoma Companies such as Santen Pharmaceuticals, Visiox Pharma Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others.
• Promising Glaucoma Therapies such as QLS-111 ophthalmic solution, (0.015%), XEN45 (Glaucoma Gel Stent), Citicoline eye drops 2%, T4090 0.2%, Netarsudil, Brimonidine, NCX 470, and others

Stay informed about the cutting-edge advancements in Glaucoma treatments. Download for updates and be a part of the revolution in care @ Glaucoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glaucoma Disease Emerging Drugs

• GmbH NCX 470: Nicox Ophthalmics
NCX 470 is a novel, second-generation nitric oxide (NO)-donating prostaglandin analog that is currently being developed by Nicox Ophthalmics. NCX-470 may assist glaucoma patients by a mechanism other than IOP lowering, notably by enhancing ocular perfusion. IOP reduction is the most common treatment for glaucoma, and preliminary studies suggest that if approved, NCX-470's dual mechanistic approach (nitric oxide donation and prostaglandin F2 activity) could make it the most effective single-agent glaucoma medicine in terms of IOP-lowering efficacy. Currently, the drug is in Phase III stage of its clinical study for the treatment of open-angle glaucoma or ocular hypertension.

• DE-126: Santen Pharmaceuticals
DE-126 (ONO-9054) is a once-daily prostaglandin eye drop drug product with a novel, dual-mode of action that activates both FP and EP3 receptors (both FP and EP3 receptors are prostaglandin receptors). As it has been reported that both receptors have an effect in reducing intraocular pressure, ONO-9054 is expected to give a new therapeutic options for the treatment of glaucoma. It is likely to show a superior IOP lowering effect compared to FP receptor agonists. Currently, the drug is in Phase III stage of its clinical study for the treatment of open-angle glaucoma or ocular hypertension.

• POLAT 001: Peregrine Ophthalmic
POLAT-001 is a sustained released product of latanoprost for the medical treatment of glaucoma. The drug is a 100 nm-long nanoliposome containing latanoprost. Lipolat is an extended release drug delivery solution that is a ground breaking development in nanomedicine for ophthalmology. Liposomal latanoprost has completed a pilot Phase IIa trial in the US for glaucoma indication.

• BTQ-1902: Betaliq, Inc.
BTQ 1902 is an EyeSol based formulation of timolol, the most commonly prescribed beta blocker. Beta blockers are one of the most commonly prescribed classes of medicines to treat glaucoma. Beta blockers reduce Intraocular Pressure (IOP) by blockade of sympathetic nerve endings in the ciliary epithelium causing a fall in aqueous humour production. Beta blockers are often prescribed in combination with other glaucoma medications. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Open-Angle Glaucoma.

• ST266: Noveome Biotherapeutics
ST266 is a non-cellular biologic drug candidate, currently considered "investigational," since it is not yet approved by the U.S. Food and Drug Administration (FDA). The clinical trials are designed to examine and confirm that ST266 is safe and effective in humans with the goal of bringing this unique product to potentially millions of patients who suffer from complex diseases and conditions in ophthalmology, neurology, dermatology-and beyond. ST266 is made by the proprietary method of culturing amnion epithelial cells that are harvested from donated full-term placentas normally discarded after birth.

Learn more about Glaucoma Drugs opportunities in our groundbreaking Glaucoma Research and development projects @ Glaucoma Unmet Needs- https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Glaucoma Companies
Santen Pharmaceuticals, Visiox Pharma Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others

Glaucoma Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Glaucoma Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Discover the latest advancements in Glaucoma treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Glaucoma Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Glaucoma Pipeline Report
• Coverage- Global
• Glaucoma Companies- Santen Pharmaceuticals, Visiox Pharma Nicox Ophthalmics, pH Pharma, Omikron Italia, Tarsier Pharma, TearClear, Laboratoires Thea, EMS, Peregrine Ophthalmic, Betaliq, Inc., Ocuphire Pharma, Inc., HK inno.N, VivaVision Biotech, Qlaris Bio, and others.
• Glaucoma Therapies- QLS-111 ophthalmic solution, (0.015%), XEN45 (Glaucoma Gel Stent), Citicoline eye drops 2%, T4090 0.2%, Netarsudil, Brimonidine, NCX 470, and others.
• Glaucoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Glaucoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Glaucoma Pipeline on our website @ Glaucoma Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/glaucoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Glaucoma Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Glaucoma Disease- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. NCX 470: Nicox Ophthalmics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. POLAT 001: Peregrine Ophthalmic
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. ST266: Noveome Biotherapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. RTC-1119: Ripple Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Glaucoma Disease Key Companies
21. Glaucoma Disease Key Products
22. Glaucoma Disease- Unmet Needs
23. Glaucoma Disease- Market Drivers and Barriers
24. Glaucoma Disease- Future Perspectives and Conclusion
25. Glaucoma Disease Analyst Views
26. Glaucoma Disease Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2024

carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market
somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.